Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Narcolepsy Type 1

Neurological & Neuromuscular

Narcolepsy Type 1 Clinical Trials and Treatments

Also called narcolepsy with cataplexy, hypocretin deficiency, orexin deficiency

Narcolepsy type 1 (NT1) is a chronic neurologic disorder caused by selective loss of hypocretin (orexin)-producing neurons in the lateral hypothalamus, resulting in pathologically low cerebrospinal fluid (CSF) hypocretin-1 levels (typically <110 pg/mL). The presenting symptom complex includes excessive daytime sleepiness (EDS) with overwhelming sleep tendency, cataplexy (sudden loss of voluntary muscle tone triggered by emotional stimuli such as laughter or surprise), sleep paralysis upon awakening or sleep onset, and hypnagogic or hypnopompic hallucinations.

In plain words, narcolepsy type 1 is a long-lasting brain condition where the nerve cells that make a wakefulness signal called hypocretin are lost. People feel very sleepy during the day and can have sudden muscle weakness set off by emotions like laughter.

Get an email when new Narcolepsy Type 1 trials open or the FDA decides. Get alerts

Narcolepsy Type 1

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 9 studies with no phase, like observational studies.

FDA review2

Pitolisant GR, Apr 1, 2027 · AXS-12, May 1, 2027

FDA-approved medicines5

Orzeyful · Wakix · Xyrem · Xywav · Lumryz

Narcolepsy Type 1 has 5 FDA-approved medicines, 21 open or active clinical trials (19 recruiting), and a pending FDA decision on Pitolisant GR, due Apr 1, 2027.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Narcolepsy Type 1

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Narcolepsy Type 1

Narcolepsy type 1 (NT1) is a chronic neurologic disorder caused by selective loss of hypocretin (orexin)-producing neurons in the lateral hypothalamus, resulting in pathologically low cerebrospinal fluid (CSF) hypocretin-1 levels (typically <110 pg/mL).

Keep reading about Narcolepsy Type 1

The presenting symptom complex includes excessive daytime sleepiness (EDS) with overwhelming sleep tendency, cataplexy (sudden loss of voluntary muscle tone triggered by emotional stimuli such as laughter or surprise), sleep paralysis upon awakening or sleep onset, and hypnagogic or hypnopompic hallucinations.

The pathophysiology appears autoimmune, supported by strong HLA-DQB1*0602 association (present in ~98% of NT1 patients versus 30-40% of general population), recent identification of hypocretin neuron-specific antibodies in some patients, and temporal association with H1N1 infection and vaccination. EDS and cataplexy profoundly impact safety, driving ability, employment, and quality of life.

Under the international sleep disorder criteria (ICSD-3), diagnosis needs daily sleepiness for at least 3 months plus either of 2 findings. One is cataplexy with a daytime nap test (MSLT) showing an average time to fall asleep of 8 minutes or less and REM sleep within 15 minutes of falling asleep in at least 2 naps; a quick REM onset on the overnight sleep study can count as 1 of them. The other is a low hypocretin-1 level in the spinal fluid, 110pg/mL or less. Prognosis is good with treatment; life expectancy is normal.

What are the symptoms of Narcolepsy Type 1?

These are common symptoms of Narcolepsy Type 1, and how strong they are varies from person to person.

  • Excessive daytime sleepiness despite adequate nighttime sleep
  • Sudden loss of muscle tone triggered by emotion (cataplexy)
  • Sleep paralysis
  • Hypnagogic/hypnopompic hallucinations
  • Fragmented nighttime sleep
  • Automatic behaviors during microsleep

Who gets Narcolepsy Type 1?

NT1 typically manifests in adolescence or young adulthood with peak incidence between ages 15-25 years, though presentation can occur as early as childhood or as late as 50 years.

The condition affects males and females equally across all ethnic groups. Strong HLA-DQB1*0602 association is present in virtually all NT1 patients and approximately 25-40% of the general population, indicating that genetic predisposition combined with environmental triggers (possibly H1N1 infection, Pandemrix vaccination, or other infectious agents) is necessary for disease development. HLA-negative NT1 cases are rare.

Geographic variation in HLA haplotype frequencies influences disease prevalence by region. Most cases are sporadic, with no clear inheritance pattern. MedlinePlus Genetics reports that parents, siblings and children of a person with narcolepsy with cataplexy have about 40 times the general population's risk of developing it.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Narcolepsy Type 1?

There are currently 5 FDA-approved medications for Narcolepsy Type 1.

oveporexton
Takeda
Search
sodium oxybate
calcium, magnesium, potassium, and sodium oxybates
sodium oxybate
Alkermes
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Narcolepsy Type 1 medicines are in trials?

Investigational medicines Trial Friend tracks for Narcolepsy Type 1, with trial results, safety findings and where each one stands.

How to get help paying for Narcolepsy Type 1 treatment

Charity funds and drugmaker programs for Narcolepsy Type 1, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · NORD RareCare
    Narcolepsy Medical Assistance fund
    Open

    Pays for: Medical and medication costs.

    The foundation says: “Accepting Applications”
  • From a charity · NORD RareCare
    Narcolepsy Premium Copay Assistance fund
    Open

    Pays for: Insurance premiums and copays.

    The foundation says: “Accepting Applications”
  • From a charity · TotalAssist (formerly PAN Foundation)
    Narcolepsy fund
    Open

    Pays for: Out-of-pocket costs for approved medications, up to $5,000 per year. Requires health insurance (any kind).

  • From a charity · The Assistance Fund
    Narcolepsy fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on October 26, 2026.

Every program and fund for Narcolepsy Type 1, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Narcolepsy Type 1

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Narcolepsy Type 1 resources

Reputable organizations and medical references for learning more about Narcolepsy Type 1, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Narcolepsy Type 1

Use this Narcolepsy Type 1 clinical trial finder to see the 19 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 18 test a treatment and 3 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Pitolisant GR, due April 1, 2027; AXS-12 (reboxetine), due May 1, 2027. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

21 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT07540897

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Intervention: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo

Sponsor: Alkermes, Inc.

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

Ages 18 Years to 70 Years
Started Aug 2026Updated yesterdayEst. Jun 2027 (~7 months)
RecruitingTreatment trialPhase 3Recently updatedNCT07455383

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

Intervention: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo

Sponsor: Alkermes, Inc.

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

Ages 18 Years to 70 Years
Started Apr 2026Updated yesterdayEst. May 2027 (~6 months)
Not yet recruitingObservational study, no treatment givenRecently updatedNCT07930728

Evolution of the Treatment of Rare Hypersomnias in a Reference Center Certified Since 2005

Intervention: Non applicable

Sponsor: Assistance Publique - Hôpitaux de Paris

Central hypersomnias are rare diseases that include narcolepsy and idiopathic hypersomnia.

The Sleep and Vigilance Center at Hôtel-Dieu has been certified as a Rare Disease Reference Center (CRMR) for these conditions since 2005.

Ages 18 Years+1 location
Expected to start Nov 2026Updated 6 days agoEst. Nov 2036 (~10 years)
RecruitingTreatment trialPhase 2/3Recently updatedNCT07646678

A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia

Intervention: TAK-360, Placebo

Sponsor: Takeda

Central hypersomnia conditions are a group of sleeping disorders where the brain has trouble keeping a person awake during the day (called excessive daytime sleepiness or EDS). These conditions usually include narcolepsy (type 1 and 2) and idiopathic hypersomnia (IH). Narcolepsy ...

Ages 18 Years to 71 Years
Started Jun 2026Updated 1 week agoEst. Jun 2031 (~4y 6m)
RecruitingTreatment trialPhase 2/3Recently updatedNCT07598708

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

Intervention: cleminorexton, Placebo

Sponsor: Centessa Pharmaceuticals (UK) Limited

Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness [EDS]). People living with these conditions might find it hard to stay alert and pay attention when they are...

Ages 18 Years to 70 Years
Started May 2026Updated 2 weeks agoEst. Sep 2027 (~10 months)
Find Narcolepsy Type 1 trials near you, ranked by distance →
Active trial locations73 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+65 more

Trial Pipeline

Apr 2023 to Nov 2031
2024
2026
2028
2030
now
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Narcolepsy Type 1 trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Narcolepsy Type 1 foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Narcolepsy Type 1 patient communities

Facebook groups, Reddit communities and YouTube channels where Narcolepsy Type 1 patients, caregivers and advocacy groups talk.

Companies developing Narcolepsy Type 1 treatments

Drugmakers that list Narcolepsy Type 1 in their rare disease portfolio, 3 in all.

Questions people ask about Narcolepsy Type 1